Healthcare >> CEO Interviews >> June 2, 2003
ROGER S. NEWTON is President and Chief Executive Officer of Esperion
Therapeutics, Inc., a biopharmaceutical company founded in July 1998 and
located in Ann Arbor, Michigan. Esperion is dedicated to the discovery
and development of pharmaceutical products for the treatment of
cardiovascular disease through the use of a treatment approach called
HDL Therapy. Dr. Newton's research interests over the past 30 years have
focused on the nutritional and pharmacological regulation of cholesterol
and lipoprotein metabolism as they relate to atherosclerosis and
vascular diseases. During his tenure at Parke-Davis from 1981 to 1998,
Dr. Newton was Chairman of the Atherosclerosis Drug Discovery Team,
during which time he co-discovered and was the product champion of what
is now the most prescribed cholesterol reducing drug in the United
States, atorvastatin (Lipitor). Dr. Newton is also an Adjunct Associate
Professor in the Department of Pharmacology at the University of
Michigan Medical School and is a member of the American Heart
Association's Council on Arteriosclerosis, Thrombosis and Vascular
Biology. He has co-authored nearly 100 peer-reviewed articles and
chapters during his research career. Profile
Therapeutics and an overview of what the company is doing at the
present time?
Dr. Newton: Esperion Therapeutics is a
